Abstract
Patients with a ROS1-rearrangement are sensitive to targeted treatment with ROS1-inhibitors. However, only 0.5-2% of NSCLC-patients harbor this activating fusion. In order to detect these cases, immunohistochemical (IHC) screening for ROS1-protein expression has been suggested. However, there is a debate about the reliability of such an assay and the comparability of available antibody clones. The aim of this study was to determine the presence of ROS1 fusions in two large NSCLC-cohorts and to evaluate the diagnostic performance of current detection strategies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
